These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

432 related items for PubMed ID: 9727024

  • 1. p35, the neuronal-specific activator of cyclin-dependent kinase 5 (Cdk5) is degraded by the ubiquitin-proteasome pathway.
    Patrick GN, Zhou P, Kwon YT, Howley PM, Tsai LH.
    J Biol Chem; 1998 Sep 11; 273(37):24057-64. PubMed ID: 9727024
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Two Degradation Pathways of the p35 Cdk5 (Cyclin-dependent Kinase) Activation Subunit, Dependent and Independent of Ubiquitination.
    Takasugi T, Minegishi S, Asada A, Saito T, Kawahara H, Hisanaga S.
    J Biol Chem; 2016 Feb 26; 291(9):4649-57. PubMed ID: 26631721
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Okadaic acid-stimulated degradation of p35, an activator of CDK5, by proteasome in cultured neurons.
    Saito T, Ishiguro K, Onuki R, Nagai Y, Kishimoto T, Hisanaga S.
    Biochem Biophys Res Commun; 1998 Nov 27; 252(3):775-8. PubMed ID: 9837783
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cyclin-dependent kinase activity is required for apoptotic death but not inclusion formation in cortical neurons after proteasomal inhibition.
    Rideout HJ, Wang Q, Park DS, Stefanis L.
    J Neurosci; 2003 Feb 15; 23(4):1237-45. PubMed ID: 12598612
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The p35/Cdk5 kinase is a neuron-specific Rac effector that inhibits Pak1 activity.
    Nikolic M, Chou MM, Lu W, Mayer BJ, Tsai LH.
    Nature; 1998 Sep 10; 395(6698):194-8. PubMed ID: 9744280
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
    Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, Inagaki M, Delcros JG, Moulinoux JP.
    Eur J Biochem; 1997 Jan 15; 243(1-2):527-36. PubMed ID: 9030781
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Phosphorylation of cyclin-dependent kinase 5 (Cdk5) at Tyr-15 is inhibited by Cdk5 activators and does not contribute to the activation of Cdk5.
    Kobayashi H, Saito T, Sato K, Furusawa K, Hosokawa T, Tsutsumi K, Asada A, Kamada S, Ohshima T, Hisanaga S.
    J Biol Chem; 2014 Jul 11; 289(28):19627-36. PubMed ID: 24872417
    [Abstract] [Full Text] [Related]

  • 18. Identification of functional domains in the neuronal Cdk5 activator protein.
    Poon RY, Lew J, Hunter T.
    J Biol Chem; 1997 Feb 28; 272(9):5703-8. PubMed ID: 9038181
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The protein SET binds the neuronal Cdk5 activator p35nck5a and modulates Cdk5/p35nck5a activity.
    Qu D, Li Q, Lim HY, Cheung NS, Li R, Wang JH, Qi RZ.
    J Biol Chem; 2002 Mar 01; 277(9):7324-32. PubMed ID: 11741927
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.